[{"id":16615,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/agent-2\/","name":"agent-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Agent.png","alt":""},"title":"AgenT","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-16 20:27:00","modifiedDate":"2026-04-23 11:21:35","modifiedDateGMT":"2026-04-23 15:21:35","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":40},"status":"publish","excerpt":"AgenT is a precision diagnostics company dedicated to transforming the prediction and monitoring of neurodegenerative diseases, with an initial focus on Alzheimer\u2019s disease. Built on more than a decade of research, AgenT has developed a strong scientific and technological foundation combining patented biomarkers, proprietary targeted mass spectrometry methods, and AI-based software. This approach enables the company to generate highly specific, clinically relevant insights from blood samples and to address a major unmet need in brain health: earlier, more scalable, and less invasive detection."},{"id":16078,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/aqemia-2\/","name":"aqemia-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-1.png","alt":""},"title":"AQEMIA","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:52:05","modifiedDate":"2026-04-22 15:45:35","modifiedDateGMT":"2026-04-22 19:45:35","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":52},"status":"publish","excerpt":"AQEMIA is a drug invention company developing novel molecules to address unmet medical needs. Its proprietary QEMI platform combines over a decade of physics-based research with state-of-the-art generative AI, enabling the rapid design of drug candidates without relying on experimental training data."},{"id":16188,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/__trashed-36\/","name":"__trashed-36","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/azfazfzefzed.png","alt":""},"title":"bYoRNA","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 19:55:05","modifiedDate":"2026-04-22 15:45:33","modifiedDateGMT":"2026-04-22 19:45:33","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":37},"status":"publish","excerpt":"bYoRNA is developing a platform for designing and manufacturing messenger RNA in yeast, rather than through in vitro transcription (IVT), to produce less immunogenic, less expensive, and more effective drugs. The target market is threefold: cancer immunotherapies, vaccines against infectious diseases, and gene therapies for rare diseases."},{"id":16384,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/_deeplife\/","name":"_deeplife","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image8-1.png","alt":""},"title":"DeepLife","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-16 20:47:16","modifiedDate":"2026-04-27 13:29:46","modifiedDateGMT":"2026-04-27 17:29:46","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":23},"status":"publish","excerpt":"DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types. Its platform, TwinCell, simulates cell-type-specific behaviour by integrating over 1 billion harmonized single-cell omics data points with causal AI, enabling more precise target identification, drug repositioning and disease understanding."},{"id":16606,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/__trashed-38\/","name":"__trashed-38","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-31.png","alt":""},"title":"Dilico","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 1, 2026","dateGMT":"2026-04-01 14:26:08","modifiedDate":"2026-04-22 15:58:09","modifiedDateGMT":"2026-04-22 19:58:09","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":35},"status":"publish","excerpt":"Dillico developed the All-ScaleFlow manufacturing platform, an end-to-end automated continuous production equipment for m\/sa\/gRNA-LNP therapeutics with related digital tools and services. This solution enables efficient in-silico process development for any mRNA therapeutics, leveraging a Performance Modeling Platform. The continuous production is scale-up free and can process batches ranging from pre-clinical or individualized medicine scale to large commercial scale. The All-ScaleFlow is a powerful tool to accelerate the advancement of m\/sa\/gRNA assets through the pipeline."},{"id":16382,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/inspek\/","name":"inspek","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image3-1.png","alt":""},"title":"InSpek","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 27, 2026","dateGMT":"2026-03-27 14:59:42","modifiedDate":"2026-04-27 13:38:50","modifiedDateGMT":"2026-04-27 17:38:50","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":20},"status":"publish","excerpt":"InSpek is a biotools company redefining bioprocess manufacturing through real-time monitoring and artificial intelligence. Its bioprocess optimization platform doesn't just analyse data \u2014 it collects it, thanks to proprietary photonic sensing technology developed at MIT and CNRS. On-chip optical sensors capture rich, multimodal process data at any scale, directly within bioreactors, without sampling and without contamination risk. This fuels AI and chemometric models that learn process dynamics, detect anomalies, and identify optimal operating conditions \u2014 enabling higher yields, lower costs, and faster scale-up."},{"id":16664,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/mabsilico-2\/","name":"mabsilico-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-65.png","alt":""},"title":"MAbSilico","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 27, 2026","dateGMT":"2026-04-27 17:47:53","modifiedDate":"2026-04-27 13:50:34","modifiedDateGMT":"2026-04-27 17:50:34","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":38},"status":"publish","excerpt":"MAbSilico is a premier TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. They empower biotech and pharmaceutical companies to significantly leverage antibody discovery risks by providing high-potential computational candidates in just a matter of days. These candidates are meticulously designed and characterized in silico and subsequently validated with state-of-the-art biological technologies, ensuring a seamless transition from digital modeling to laboratory success. By combining sophisticated 3D modeling, complex interaction simulations, and advanced linear sequence analysis, MAbSilico defines antibody drug candidates through a rigorous assessment of their epitope, affinity, off-target risk, cross-species reactivity, and developability, ensuring they are fully prepared for biological activity evaluation."},{"id":16189,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/netri-2\/","name":"netri-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image25.png","alt":""},"title":"NETRI","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:51:31","modifiedDate":"2026-04-22 15:45:29","modifiedDateGMT":"2026-04-22 19:45:29","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":54},"status":"publish","excerpt":"NETRI is an innovative industrial Techbio whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-Sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology, immunology, neurological disorders, neurotoxicity and dermatology."},{"id":16879,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/theremia\/","name":"theremia","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-32.png","alt":""},"title":"Theremia","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 14, 2026","dateGMT":"2026-04-14 14:14:09","modifiedDate":"2026-04-27 13:30:16","modifiedDateGMT":"2026-04-27 17:30:16","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":44},"status":"publish","excerpt":"Theremia is a precision medicine company specialized in neurology and psychiatry. Theremia develops explainable and causal AI models to help biotech and pharma companies de-risk and optimize drug development."},{"id":16079,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/whitelab-genomics-2\/","name":"whitelab-genomics-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image10.png","alt":""},"title":"WhiteLab Genomics","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:53:02","modifiedDate":"2026-04-22 15:45:26","modifiedDateGMT":"2026-04-22 19:45:26","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":47},"status":"publish","excerpt":"WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks."}]